NU100 is a proprietary recombinant human interferon beta-1b (IFN beta-1b) which utilizes the company’s refolding process technology being developed as a new molecular entity.
The double-blind, placebo-controlled, randomized trial is designed to assess the safety and efficacy of NU100.
The company is enrolling 500 patients from125 clinical sites across Europe and Asia.
The trial will randomize patients to receive NU100 or placebo and will be treated over a 12-month period.
Nuron Biotech Clinical and Medical Affairs vice president Tracy Goeken said they expect data from this study in late 2013.